Scilex Holding Company Amortization of Debt Issuance Costs and Discounts
Scilex Holding Company (SCLX) reported Amortization of Debt Issuance Costs and Discounts of $2.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-14
- Scilex Holding Company amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $987.00K.
- Scilex Holding Company amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $1.03M.
- Scilex Holding Company amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $409.00K, a 84.23% increase year-over-year.
- Scilex Holding Company amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company amortization of debt issuance costs and discounts for fiscal 2025 was $409.00K, a 29.43% increase from fiscal 2024.
- Scilex Holding Company amortization of debt issuance costs and discounts for fiscal 2024 was $316.00K, a 386.15% increase from fiscal 2023.
- Scilex Holding Company amortization of debt issuance costs and discounts for fiscal 2023 was $65.00K, a 97.93% decline from fiscal 2022.
- Scilex Holding Company amortization of debt issuance costs and discounts for fiscal 2022 was $3.14M, a 60.27% decline from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 6 month as first filed | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 9 month as first filed | Amortization of Debt Issuance Costs and Discounts 12 month | Amortization of Debt Issuance Costs and Discounts 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $987.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $2.02M 10-Q · filed 2026-08-14 | $2.42M derived: sum of 3 quarters · filed 2026-08-14 | $2.42M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-20 | $1.44M derived: sum of 2 quarters · filed 2026-05-20 | $1.44M derived: sum of 3 quarters · filed 2026-05-20 | $1.44M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $409.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $409.00K derived: sum of 2 quarters · filed 2026-04-10 | $409.00K derived: sum of 3 quarters · filed 2026-08-14 | $409.00K 10-K · filed 2026-04-10 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-14 | $0.00 10-Q · filed 2025-11-14 | $222.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $0.00 10-Q · filed 2026-08-14 | $222.00K derived: sum of 3 quarters · filed 2026-08-14 | $253.00K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-20 | $222.00K derived: sum of 2 quarters · filed 2026-05-20 | $253.00K derived: sum of 3 quarters · filed 2026-05-20 | $285.00K derived: sum of 4 quarters · filed 2026-05-20 | |||
| 2024-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $253.00K derived: sum of 2 quarters · filed 2026-04-10 | $285.00K derived: sum of 3 quarters · filed 2026-04-10 | $316.00K 10-K · filed 2026-04-10 | |||
| 2024-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $63.00K derived: sum of 2 quarters · filed 2025-11-14 | $94.00K 10-Q · filed 2025-11-14 | $125.00K derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $63.00K 10-Q · filed 2025-08-13 | $94.00K derived: sum of 3 quarters · filed 2025-08-13 | $127.00K derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | $31.00K 10-Q · filed 2025-05-14 | $62.00K derived: sum of 2 quarters · filed 2025-05-14 | $95.00K derived: sum of 3 quarters · filed 2025-05-14 | $96.00K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $64.00K derived: sum of 2 quarters · filed 2025-03-31 | $65.00K derived: sum of 3 quarters · filed 2025-03-31 | $65.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $34.00K derived: sum of 2 quarters · filed 2025-01-17 | $34.00K 10-Q · filed 2025-01-17 | $68.00K derived: sum of 4 quarters · filed 2025-01-17 | |||
| 2023-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.00K 10-Q · filed 2024-08-13 | $35.00K derived: sum of 3 quarters · filed 2024-08-13 | $86.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $34.00K derived: sum of 2 quarters · filed 2024-05-13 | $85.00K derived: sum of 3 quarters · filed 2024-05-13 | $1.29M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $85.00K derived: sum of 2 quarters · filed 2024-03-12 | $1.29M derived: sum of 3 quarters · filed 2024-03-12 | $3.14M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.26M derived: sum of 2 quarters · filed 2023-11-14 | $3.11M 10-Q · filed 2023-11-14 | $0.00 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $3.06M 10-Q · filed 2023-08-11 | $1.16K 10-Q · filed 2022-08-12 | ||||
| 2022-03-31 | $1.85M 10-Q · filed 2023-05-12 | ||||||
| 2021-12-31 | $7.91M 10-K · filed 2024-03-12 | $16.90K 10-Q · filed 2022-08-12 | |||||
| 2020-12-31 | $10.66M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |